{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T12:51:41Z","timestamp":1793278301453,"version":"4.5.0"},"reference-count":166,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2016,10,7]],"date-time":"2016-10-07T00:00:00Z","timestamp":1475798400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004836","name":"Det Frie Forskningsr\u00e5d","doi-asserted-by":"publisher","award":["DFF-4092-00122"],"award-info":[{"award-number":["DFF-4092-00122"]}],"id":[{"id":"10.13039\/501100004836","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Danish Cancer Society and TV2s \"Kn\u00e6ck-Cancer-Program\""},{"name":"The Danish Research Council"},{"name":"The Novo Nordic Foundation"},{"name":"The Novo Nordic Foundation Tandem Program"},{"name":"The Lundbeck Foundation"},{"DOI":"10.13039\/100008363","name":"The Danish Cancer Society","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008363","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Semin Immunopathol"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1007\/s00281-016-0594-9","type":"journal-article","created":{"date-parts":[[2016,10,7]],"date-time":"2016-10-07T11:07:53Z","timestamp":1475838473000},"page":"269-282","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":155,"title":["Malignant inflammation in cutaneous T\u2010cell lymphoma\u2014a hostile takeover"],"prefix":"10.1007","volume":"39","author":[{"given":"Thorbj\u00f8rn","family":"Krejsgaard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lise M.","family":"Lindahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigel P.","family":"Mongan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariusz A.","family":"Wasik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan V.","family":"Litvinov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Iversen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Langhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Woetmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"Odum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,10,7]]},"reference":[{"key":"594_CR1","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1182\/blood-2004-09-3502","volume":"105","author":"R Willemze","year":"2005","unstructured":"Willemze R, Jaffe ES, Burg G et al (2005) WHO-EORTC classification for cutaneous lymphomas. Blood 105:3768\u20133785","journal-title":"Blood"},{"key":"594_CR2","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1111\/bjd.12909","volume":"170","author":"JJ Scarisbrick","year":"2014","unstructured":"Scarisbrick JJ, Kim YH, Whittaker SJ et al (2014) Prognostic factors, prognostic indices and staging in mycosis fungoides and Sezary syndrome: where are we now? Br J Dermatol 170:1226\u20131236","journal-title":"Br J Dermatol"},{"key":"594_CR3","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/ajh.24233","volume":"91","author":"RA Wilcox","year":"2016","unstructured":"Wilcox RA (2016) Cutaneous T-cell lymphoma: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol 91:151\u2013165","journal-title":"Am J Hematol"},{"key":"594_CR4","doi-asserted-by":"crossref","first-page":"4730","DOI":"10.1200\/JCO.2009.27.7665","volume":"28","author":"NS Agar","year":"2010","unstructured":"Agar NS, Wedgeworth E, Crichton S et al (2010) Survival outcomes and prognostic factors in mycosis fungoides\/Sezary syndrome: validation of the revised International Society for Cutaneous Lymphomas\/European Organisation for Research and Treatment of Cancer staging proposal. J Clin Oncol 28:4730\u20134739","journal-title":"J Clin Oncol"},{"key":"594_CR5","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.1200\/JCO.2015.61.7142","volume":"33","author":"JJ Scarisbrick","year":"2015","unstructured":"Scarisbrick JJ, Prince HM, Vermeer MH et al (2015) Cutaneous lymphoma international consortium study of outcome in advanced stages of mycosis fungoides and Sezary syndrome: effect of specific prognostic markers on survival and development of a prognostic model. J Clin Oncol 33:3766\u20133773","journal-title":"J Clin Oncol"},{"key":"594_CR6","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1309\/YB79JG4TMJERQ7PV","volume":"123","author":"AH Diwan","year":"2005","unstructured":"Diwan AH, Prieto VG, Herling M et al (2005) Primary Sezary syndrome commonly shows low-grade cytologic atypia and an absence of epidermotropism. Am J Clin Pathol 123:510\u2013515","journal-title":"Am J Clin Pathol"},{"key":"594_CR7","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1046\/j.1523-1747.2002.19610.x","volume":"119","author":"K Ferenczi","year":"2002","unstructured":"Ferenczi K, Fuhlbrigge RC, Pinkus J et al (2002) Increased CCR4 expression in cutaneous T cell lymphoma. J Invest Dermatol 119:1405\u20131410","journal-title":"J Invest Dermatol"},{"key":"594_CR8","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1046\/j.1523-1747.2003.12555.x","volume":"121","author":"T Kallinich","year":"2003","unstructured":"Kallinich T, Muche JM, Qin S et al (2003) Chemokine receptor expression on neoplastic and reactive T cells in the skin at different stages of mycosis fungoides. J Invest Dermatol 121:1045\u20131052","journal-title":"J Invest Dermatol"},{"key":"594_CR9","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1182\/blood-2009-11-251926","volume":"116","author":"JJ Campbell","year":"2010","unstructured":"Campbell JJ, Clark RA, Watanabe R et al (2010) Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors. Blood 116:767\u2013771","journal-title":"Blood"},{"key":"594_CR10","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/1346-8138.12852","volume":"42","author":"M Sugaya","year":"2015","unstructured":"Sugaya M, Morimura S, Suga H et al (2015) CCR4 is expressed on infiltrating cells in lesional skin of early mycosis fungoides and atopic dermatitis. J Dermatol 42:613\u2013615","journal-title":"J Dermatol"},{"key":"594_CR11","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1158\/1078-0432.CCR-05-1513","volume":"12","author":"Y Fujita","year":"2006","unstructured":"Fujita Y, Abe R, Sasaki M et al (2006) Presence of circulating CCR10+ T cells and elevated serum CTACK\/CCL27 in the early stage of mycosis fungoides. Clin Cancer Res 12:2670\u20132675","journal-title":"Clin Cancer Res"},{"key":"594_CR12","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1309\/3N7P-J84L-JQ9K-G89R","volume":"115","author":"D Lu","year":"2001","unstructured":"Lu D, Duvic M, Medeiros LJ et al (2001) The T-cell chemokine receptor CXCR3 is expressed highly in low-grade mycosis fungoides. Am J Clin Pathol 115:413\u2013421","journal-title":"Am J Clin Pathol"},{"key":"594_CR13","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1046\/j.1523-1747.1998.00263.x","volume":"111","author":"CP Tensen","year":"1998","unstructured":"Tensen CP, Vermeer MH, van der Stoop PM et al (1998) Epidermal interferon-gamma inducible protein-10 (IP-10) and monokine induced by gamma-interferon (Mig) but not IL-8 mRNA expression is associated with epidermotropism in cutaneous T cell lymphomas. J Invest Dermatol 111:222\u2013226","journal-title":"J Invest Dermatol"},{"key":"594_CR14","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/1346-8138.12305","volume":"41","author":"T Miyagaki","year":"2014","unstructured":"Miyagaki T, Sugaya M (2014) Immunological milieu in mycosis fungoides and Sezary syndrome. J Dermatol 41:11\u201318","journal-title":"J Dermatol"},{"key":"594_CR15","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/leu.2011.237","volume":"26","author":"T Krejsgaard","year":"2012","unstructured":"Krejsgaard T, Odum N, Geisler C et al (2012) Regulatory T cells and immunodeficiency in mycosis fungoides and Sezary syndrome. Leukemia 26:424\u2013432","journal-title":"Leukemia"},{"key":"594_CR16","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1002\/cam4.472","volume":"4","author":"IV Litvinov","year":"2015","unstructured":"Litvinov IV, Tetzlaff MT, Rahme E et al (2015) Demographic patterns of cutaneous T-cell lymphoma incidence in Texas based on two different cancer registries. Cancer Med 4:1440\u20131447","journal-title":"Cancer Med"},{"key":"594_CR17","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1002\/cncr.29301","volume":"121","author":"IV Litvinov","year":"2015","unstructured":"Litvinov IV, Tetzlaff MT, Rahme E et al (2015) Identification of geographic clustering and regions spared by cutaneous T-cell lymphoma in Texas using 2 distinct cancer registries. Cancer 121:1993\u20132003","journal-title":"Cancer"},{"key":"594_CR18","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.3390\/toxins5081402","volume":"5","author":"A Willerslev-Olsen","year":"2013","unstructured":"Willerslev-Olsen A, Krejsgaard T, Lindahl LM et al (2013) Bacterial toxins fuel disease progression in cutaneous T-cell lymphoma. Toxins (Basel) 5:1402\u20131421","journal-title":"Toxins (Basel)"},{"key":"594_CR19","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1038\/ng.3356","volume":"47","author":"J Choi","year":"2015","unstructured":"Choi J, Goh G, Walradt T et al (2015) Genomic landscape of cutaneous T cell lymphoma. Nat Genet 47:1011\u20131019","journal-title":"Nat Genet"},{"key":"594_CR20","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1038\/ng.3370","volume":"47","author":"A Ungewickell","year":"2015","unstructured":"Ungewickell A, Bhaduri A, Rios E et al (2015) Genomic analysis of mycosis fungoides and Sezary syndrome identifies recurrent alterations in TNFR2. Nat Genet 47:1056\u20131060","journal-title":"Nat Genet"},{"key":"594_CR21","doi-asserted-by":"crossref","unstructured":"Kiel MJ, Sahasrabuddhe AA, Rolland DC et al (2015) Genomic analyses reveal recurrent mutations in epigenetic modifiers and the JAK-STAT pathway in Sezary syndrome. Nat Commun 6","DOI":"10.1038\/ncomms9470"},{"key":"594_CR22","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1038\/ng.3444","volume":"47","author":"L Wang","year":"2015","unstructured":"Wang L, Ni X, Covington KR et al (2015) Genomic profiling of Sezary syndrome identifies alterations of key T cell signaling and differentiation genes. Nat Genet 47:1426\u20131434","journal-title":"Nat Genet"},{"key":"594_CR23","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1038\/ng.3442","volume":"47","author":"AC Silva Almeida da","year":"2015","unstructured":"da Silva Almeida AC, Abate F, Khiabanian H et al (2015) The mutational landscape of cutaneous T cell lymphoma and Sezary syndrome. Nat Genet 47:1465\u20131470","journal-title":"Nat Genet"},{"key":"594_CR24","doi-asserted-by":"crossref","first-page":"3387","DOI":"10.1182\/blood-2016-02-699843","volume":"127","author":"WJ Woollard","year":"2016","unstructured":"Woollard WJ, Pullabhatla V, Lorenc A et al (2016) Candidate driver genes in Sezary syndrome: frequent perturbations of genes involved in genome maintenance and DNA repair. Blood 127:3387\u20133397","journal-title":"Blood"},{"key":"594_CR25","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1182\/blood-2014-11-611194","volume":"126","author":"LY McGirt","year":"2015","unstructured":"McGirt LY, Jia P, Baerenwald DA et al (2015) Whole-genome sequencing reveals oncogenic mutations in mycosis fungoides. Blood 126:508\u2013519","journal-title":"Blood"},{"key":"594_CR26","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1053\/j.seminoncol.2012.01.010","volume":"39","author":"B Belloni","year":"2012","unstructured":"Belloni B, Johansen N, Glass LF et al (2012) Recent advances in the management of cutaneous lymphomas. Semin Oncol 39:150\u2013162","journal-title":"Semin Oncol"},{"key":"594_CR27","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1172\/JCI200524826","volume":"115","author":"EJ Kim","year":"2005","unstructured":"Kim EJ, Hess S, Richardson SK et al (2005) Immunopathogenesis and therapy of cutaneous T cell lymphoma. J Clin Invest 115:798\u2013812","journal-title":"J Clin Invest"},{"key":"594_CR28","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1600-0560.1994.tb00250.x","volume":"21","author":"GS Wood","year":"1994","unstructured":"Wood GS, Edinger A, Hoppe RT et al (1994) Mycosis fungoides skin lesions contain CD8+ tumor-infiltrating lymphocytes expressing an activated, MHC-restricted cytotoxic T-lymphocyte phenotype. J Cutan Pathol 21:151\u2013156","journal-title":"J Cutan Pathol"},{"key":"594_CR29","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/1523-1747.ep12292129","volume":"108","author":"K Asadullah","year":"1997","unstructured":"Asadullah K, Friedrich M, Docke WD et al (1997) Enhanced expression of T-cell activation and natural killer cell antigens indicates systemic anti-tumor response in early primary cutaneous T-cell lymphoma. J Invest Dermatol 108:743\u2013747","journal-title":"J Invest Dermatol"},{"key":"594_CR30","doi-asserted-by":"crossref","first-page":"4331","DOI":"10.1182\/blood.V91.11.4331","volume":"91","author":"M Bagot","year":"1998","unstructured":"Bagot M, Echchakir H, Mami-Chouaib F et al (1998) Isolation of tumor-specific cytotoxic CD4+ and CD4\u00a0+\u00a0CD8dim\u00a0+\u00a0T-cell clones infiltrating a cutaneous T-cell lymphoma. Blood 91:4331\u20134341","journal-title":"Blood"},{"key":"594_CR31","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1046\/j.1523-1747.2000.00995.x","volume":"115","author":"H Echchakir","year":"2000","unstructured":"Echchakir H, Bagot M, Dorothee G et al (2000) Cutaneous T cell lymphoma reactive CD4+ cytotoxic T lymphocyte clones display a Th1 cytokine profile and use a fas-independent pathway for specific tumor cell lysis. J Invest Dermatol 115:74\u201380","journal-title":"J Invest Dermatol"},{"key":"594_CR32","doi-asserted-by":"crossref","first-page":"4322","DOI":"10.1200\/JCO.2001.19.23.4322","volume":"19","author":"MH Vermeer","year":"2001","unstructured":"Vermeer MH, van Doom R, Dukers D et al (2001) CD8+ T cells in cutaneous T-cell lymphoma: expression of cytotoxic proteins, Fas ligand, and killing inhibitory receptors and their relationship with clinical behavior. J Clin Oncol 19:4322\u20134329","journal-title":"J Clin Oncol"},{"key":"594_CR33","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jaad.2014.09.022","volume":"72","author":"AC Hsi","year":"2015","unstructured":"Hsi AC, Lee SJ, Rosman IS et al (2015) Expression of helper T cell master regulators in inflammatory dermatoses and primary cutaneous T-cell lymphomas: diagnostic implications. J Am Acad Dermatol 72:159\u2013167","journal-title":"J Am Acad Dermatol"},{"key":"594_CR34","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/0190-9622(95)90067-5","volume":"32","author":"RT Hoppe","year":"1995","unstructured":"Hoppe RT, Medeiros LJ, Warnke RA et al (1995) CD8-positive tumor-infiltrating lymphocytes influence the long-term survival of patients with mycosis fungoides. J Am Acad Dermatol 32:448\u2013453","journal-title":"J Am Acad Dermatol"},{"key":"594_CR35","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/1523-1747.ep12363378","volume":"107","author":"CL Berger","year":"1996","unstructured":"Berger CL, Wang N, Christensen I et al (1996) The immune response to class I-associated tumor-specific cutaneous T-cell lymphoma antigens. J Invest Dermatol 107:392\u2013397","journal-title":"J Invest Dermatol"},{"key":"594_CR36","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1111\/j.0022-202X.2005.23914.x","volume":"125","author":"JD Bouaziz","year":"2005","unstructured":"Bouaziz JD, Ortonne N, Giustiniani J et al (2005) Circulating natural killer lymphocytes are potential cytotoxic effectors against autologous malignant cells in Sezary syndrome patients. J Invest Dermatol 125:1273\u20131278","journal-title":"J Invest Dermatol"},{"key":"594_CR37","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/j.1365-2133.2005.06755.x","volume":"153","author":"D Abeni","year":"2005","unstructured":"Abeni D, Frontani M, Sampogna F et al (2005) Circulating CD8+ lymphocytes, white blood cells, and survival in patients with mycosis fungoides. Br J Dermatol 153:324\u2013330","journal-title":"Br J Dermatol"},{"key":"594_CR38","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/1523-1747.ep12398454","volume":"103","author":"BR Vowels","year":"1994","unstructured":"Vowels BR, Lessin SR, Cassin M et al (1994) Th2 cytokine mRNA expression in skin in cutaneous T-cell lymphoma. J Invest Dermatol 103:669\u2013673","journal-title":"J Invest Dermatol"},{"key":"594_CR39","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1046\/j.1365-2133.2003.05224.x","volume":"148","author":"E Papadavid","year":"2003","unstructured":"Papadavid E, Economidou J, Psarra A et al (2003) The relevance of peripheral blood T-helper 1 and 2 cytokine pattern in the evaluation of patients with mycosis fungoides and Sezary syndrome. Br J Dermatol 148:709\u2013718","journal-title":"Br J Dermatol."},{"key":"594_CR40","doi-asserted-by":"crossref","first-page":"4812","DOI":"10.1158\/1078-0432.CCR-06-0532","volume":"12","author":"S Hahtola","year":"2006","unstructured":"Hahtola S, Tuomela S, Elo L et al (2006) Th1 response and cytotoxicity genes are down-regulated in cutaneous T-cell lymphoma. Clin Cancer Res 12:4812\u20134821","journal-title":"Clin Cancer Res"},{"key":"594_CR41","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1182\/blood-2014-07-590398","volume":"125","author":"LJ Geskin","year":"2015","unstructured":"Geskin LJ, Viragova S, Stolz DB et al (2015) Interleukin-13 is overexpressed in cutaneous T-cell lymphoma cells and regulates their proliferation. Blood 125:2798\u20132805","journal-title":"Blood"},{"key":"594_CR42","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1111\/jdv.12299","volume":"28","author":"VE Johnson","year":"2014","unstructured":"Johnson VE, Vonderheid EC, Hess AD et al (2014) Genetic markers associated with progression in early mycosis fungoides. J Eur Acad Dermatol Venereol 28:1431\u20131435","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"594_CR43","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.4161\/15384101.2014.965061","volume":"13","author":"E Netchiporouk","year":"2014","unstructured":"Netchiporouk E, Litvinov IV, Moreau L et al (2014) Deregulation in STAT signaling is important for cutaneous T-cell lymphoma (CTCL) pathogenesis and cancer progression. Cell Cycle 13:3331\u20133335","journal-title":"Cell Cycle"},{"key":"594_CR44","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1001\/jama.1992.03480100060031","volume":"267","author":"PI Axelrod","year":"1992","unstructured":"Axelrod PI, Lorber B, Vonderheid EC (1992) Infections complicating mycosis fungoides and Sezary syndrome. JAMA 267:1354\u20131358","journal-title":"JAMA"},{"key":"594_CR45","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1038\/jid.2011.470","volume":"132","author":"T Miyagaki","year":"2012","unstructured":"Miyagaki T, Sugaya M, Suga H et al (2012) Low herpesvirus entry mediator (HVEM) expression on dermal fibroblasts contributes to a Th2-dominant microenvironment in advanced cutaneous T-cell lymphoma. J Invest Dermatol 132:1280\u20131289","journal-title":"Invest Dermatol"},{"key":"594_CR46","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1038\/ni.f.213","volume":"9","author":"SK Bromley","year":"2008","unstructured":"Bromley SK, Mempel TR, Luster AD (2008) Orchestrating the orchestrators: chemokines in control of T cell traffic. Nat Immunol 9:970\u2013980","journal-title":"Nat Immunol"},{"key":"594_CR47","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1067\/mjd.2003.132","volume":"48","author":"T Kakinuma","year":"2003","unstructured":"Kakinuma T, Sugaya M, Nakamura K et al (2003) Thymus and activation-regulated chemokine (TARC\/CCL17) in mycosis fungoides: serum TARC levels reflect the disease activity of mycosis fungoides. J Am Acad Dermatol 48:23\u201330","journal-title":"J Am Acad Dermatol"},{"key":"594_CR48","doi-asserted-by":"crossref","first-page":"e60","DOI":"10.1111\/j.1468-3083.2012.04495.x","volume":"27","author":"T Miyagaki","year":"2013","unstructured":"Miyagaki T, Sugaya M, Suga H et al (2013) Increased CCL18 expression in patients with cutaneous T-cell lymphoma: association with disease severity and prognosis. J Eur Acad Dermatol Venereol 27:e60\u2013e67","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"594_CR49","doi-asserted-by":"crossref","first-page":"440","DOI":"10.3109\/10428194.2014.919634","volume":"56","author":"M Tuzova","year":"2015","unstructured":"Tuzova M, Richmond J, Wolpowitz D et al (2015) CCR4+ T cell recruitment to the skin in mycosis fungoides: potential contributions by thymic stromal lymphopoietin and interleukin-16. Leuk Lymphoma 56:440\u2013449","journal-title":"Leuk Lymphoma"},{"key":"594_CR50","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1038\/jid.2010.128","volume":"130","author":"T Miyagaki","year":"2010","unstructured":"Miyagaki T, Sugaya M, Fujita H et al (2010) Eotaxins and CCR3 interaction regulates the Th2 environment of cutaneous T-cell lymphoma. J Invest Dermatol 130:2304\u20132311","journal-title":"Invest Dermatol"},{"key":"594_CR51","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/j.ajpath.2011.05.040","volume":"179","author":"C Gunther","year":"2011","unstructured":"Gunther C, Zimmermann N, Berndt N et al (2011) Up-regulation of the chemokine CCL18 by macrophages is a potential immunomodulatory pathway in cutaneous T-cell lymphoma. Am J Pathol 179:1434\u20131442","journal-title":"Am J Pathol"},{"key":"594_CR52","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1126\/science.277.5334.2005","volume":"277","author":"F Sallusto","year":"1997","unstructured":"Sallusto F, Mackay CR, Lanzavecchia A (1997) Selective expression of the eotaxin receptor CCR3 by human T helper 2 cells. Science 277:2005\u20132007","journal-title":"Science"},{"key":"594_CR53","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1084\/jem.20130240","volume":"210","author":"SA Islam","year":"2013","unstructured":"Islam SA, Ling MF, Leung J et al (2013) Identification of human CCR8 as a CCL18 receptor. J Exp Med 210:1889\u20131898","journal-title":"J Exp Med"},{"key":"594_CR54","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1182\/blood-2014-09-600924","volume":"125","author":"M Duvic","year":"2015","unstructured":"Duvic M, Pinter-Brown LC, Foss FM et al (2015) Phase 1\/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma. Blood 125:1883\u20131889","journal-title":"Blood"},{"key":"594_CR55","doi-asserted-by":"crossref","first-page":"7529","DOI":"10.1158\/1078-0432.CCR-11-1192","volume":"17","author":"T Miyagaki","year":"2011","unstructured":"Miyagaki T, Sugaya M, Suga H et al (2011) IL-22, but not IL-17, dominant environment in cutaneous T-cell lymphoma. Clin Cancer Res 17:7529\u20137538","journal-title":"Clin Cancer Res"},{"key":"594_CR56","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1182\/blood-2013-09-527739","volume":"123","author":"M Ito","year":"2014","unstructured":"Ito M, Teshima K, Ikeda S et al (2014) Micro RNA-150 inhibits tumor invasion and metastasis by targeting the chemokine receptor CCR6, in advanced cutaneous T-cell lymphoma. Blood 123:1499\u20131511","journal-title":"Blood"},{"key":"594_CR57","doi-asserted-by":"crossref","first-page":"13563","DOI":"10.18632\/oncotarget.6916","volume":"7","author":"S Ikeda","year":"2016","unstructured":"Ikeda S, Kitadate A, Ito M et al (2016) Disruption of CCL20-CCR6 interaction inhibits metastasis of advanced cutaneous T-cell lymphoma. Oncotarget 7:13563\u201313574","journal-title":"Oncotarget"},{"key":"594_CR58","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1111\/1523-1747.ep12330869","volume":"107","author":"K Asadullah","year":"1996","unstructured":"Asadullah K, Docke WD, Haeussler A et al (1996) Progression of mycosis fungoides is associated with increasing cutaneous expression of interleukin-10 mRNA. J Invest Dermatol 107:833\u2013837","journal-title":"J Invest Dermatol"},{"key":"594_CR59","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1034\/j.1600-0625.2000.009004248.x","volume":"9","author":"K Asadullah","year":"2000","unstructured":"Asadullah K, Haeussler-Quade A, Gellrich S et al (2000) IL-15 and IL-16 overexpression in cutaneous T-cell lymphomas: stage-dependent increase in mycosis fungoides progression. Exp Dermatol 9:248\u2013251","journal-title":"Exp Dermatol"},{"key":"594_CR60","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1158\/2159-8290.CD-15-1297","volume":"6","author":"A Mishra","year":"2016","unstructured":"Mishra A, La PK, Kwiatkowski S et al (2016) Mechanism, consequences and therapeutic targeting of abnormal IL-15 signaling in cutaneous T-cell lymphoma. Cancer Discov 6:986\u20131005","journal-title":"Cancer Discov"},{"key":"594_CR61","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1046\/j.1523-1747.1999.00717.x","volume":"113","author":"V Blaschke","year":"1999","unstructured":"Blaschke V, Reich K, Middel P et al (1999) Expression of the CD4+ cell-specific chemoattractant interleukin-16 in mycosis fungoides. J Invest Dermatol 113:658\u2013663","journal-title":"Invest Dermatol"},{"key":"594_CR62","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1182\/blood-2013-01-480889","volume":"122","author":"T Krejsgaard","year":"2013","unstructured":"Krejsgaard T, Litvinov IV, Wang Y et al (2013) Elucidating the role of interleukin-17F in cutaneous T-cell lymphoma. Blood 122:943\u2013950","journal-title":"Blood"},{"key":"594_CR63","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1038\/jid.2012.117","volume":"132","author":"MS Kester van","year":"2012","unstructured":"van Kester MS, Borg MK, Zoutman WH et al (2012) A meta-analysis of gene expression data identifies a molecular signature characteristic for tumor-stage mycosis fungoides. J Invest Dermatol 132:2050\u20132059","journal-title":"Invest Dermatol"},{"key":"594_CR64","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1158\/2326-6066.CIR-13-0199-T","volume":"2","author":"H Ohmatsu","year":"2014","unstructured":"Ohmatsu H, Humme D, Gulati N et al (2014) IL32 is progressively expressed in mycosis fungoides independent of helper T-cell 2 and helper T-cell 9 polarization. Cancer Immunol Res 2:890\u2013900","journal-title":"Cancer Immunol Res"},{"key":"594_CR65","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1038\/jid.2013.488","volume":"134","author":"H Suga","year":"2014","unstructured":"Suga H, Sugaya M, Miyagaki T et al (2014) The role of IL-32 in cutaneous T-cell lymphoma. J Invest Dermatol 134:1428\u20131435","journal-title":"J Invest Dermatol."},{"key":"594_CR66","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.4049\/jimmunol.154.3.1491","volume":"154","author":"AH Rook","year":"1995","unstructured":"Rook AH, Kubin M, Cassin M et al (1995) IL-12 reverses cytokine and immune abnormalities in Sezary syndrome. J Immunol 154:1491\u20131498","journal-title":"J Immunol"},{"key":"594_CR67","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.1182\/blood-2009-05-220111","volume":"114","author":"RA Wilcox","year":"2009","unstructured":"Wilcox RA, Wada DA, Ziesmer SC et al (2009) Monocytes promote tumor cell survival in T-cell lymphoproliferative disorders and are impaired in their ability to differentiate into mature dendritic cells. Blood 114:2936\u20132944","journal-title":"Blood"},{"key":"594_CR68","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1038\/leu.2008.224","volume":"22","author":"T Krejsgaard","year":"2008","unstructured":"Krejsgaard T, Gjerdrum LM, Ralfkiaer E et al (2008) Malignant Tregs express low molecular splice forms of FOXP3 in Sezary syndrome. Leukemia 22:2230\u20132239","journal-title":"Leukemia"},{"key":"594_CR69","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s10875-010-9464-8","volume":"31","author":"J Richmond","year":"2011","unstructured":"Richmond J, Tuzova M, Parks A et al (2011) Interleukin-16 as a marker of Sezary syndrome onset and stage. J Clin Immunol 31:39\u201350","journal-title":"J Clin Immunol"},{"key":"594_CR70","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/ijc.20373","volume":"112","author":"A Ciree","year":"2004","unstructured":"Ciree A, Michel L, Camilleri-Broet S et al (2004) Expression and activity of IL-17 in cutaneous T-cell lymphomas (mycosis fungoides and Sezary syndrome. Int J Cancer 112:113\u2013120","journal-title":"Int J Cancer"},{"key":"594_CR71","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1038\/jid.2011.27","volume":"131","author":"T Krejsgaard","year":"2011","unstructured":"Krejsgaard T, Ralfkiaer U, Clasen-Linde E et al (2011) Malignant cutaneous T-cell lymphoma cells express IL-17 utilizing the Jak3\/Stat 3 signaling pathway. J Invest Dermatol 131:1331\u20131338","journal-title":"J Invest Dermatol"},{"key":"594_CR72","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/j.1365-2133.2011.10647.x","volume":"166","author":"L Fontao","year":"2012","unstructured":"Fontao L, Brembilla NC, Masouye I et al (2012) Interleukin-17 expression in neutrophils and Th17 cells in cutaneous T-cell lymphoma associated with neutrophilic infiltrate of the skin. Br J Dermatol 166:687\u2013689","journal-title":"Br J Dermatol"},{"key":"594_CR73","doi-asserted-by":"crossref","first-page":"5507","DOI":"10.1158\/1078-0432.CCR-14-0707","volume":"20","author":"K Wolk","year":"2014","unstructured":"Wolk K, Mitsui H, Witte K et al (2014) Deficient cutaneous antibacterial competence in cutaneous T-cell lymphomas: role of Th2-mediated biased Th17 function. Clin Cancer Res 20:5507\u20135516","journal-title":"Clin Cancer Res"},{"key":"594_CR74","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1001\/archderm.141.3.353","volume":"141","author":"N Franck","year":"2005","unstructured":"Franck N, Carlotti A, Gorin I et al (2005) Mycosis fungoides-type cutaneous T-cell lymphoma and neutrophilic dermatosis. Arch Dermatol 141:353\u2013356","journal-title":"Arch Dermatol"},{"key":"594_CR75","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1182\/blood.V99.3.973","volume":"99","author":"M Nielsen","year":"2002","unstructured":"Nielsen M, Nissen MH, Gerwien J et al (2002) Spontaneous interleukin-5 production in cutaneous T-cell lymphoma lines is mediated by constitutively activated stat 3. Blood 99:973\u2013977","journal-title":"Blood"},{"key":"594_CR76","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.1158\/1078-0432.CCR-12-3488","volume":"19","author":"E Guenova","year":"2013","unstructured":"Guenova E, Watanabe R, Teague JE et al (2013) TH2 cytokines from malignant cells suppress TH1 responses and enforce a global TH2 bias in leukemic cutaneous T-cell lymphoma. Clin Cancer Res 19:3755\u20133763","journal-title":"Clin Cancer Res"},{"key":"594_CR77","doi-asserted-by":"crossref","first-page":"9148","DOI":"10.1073\/pnas.93.17.9148","volume":"93","author":"Q Zhang","year":"1996","unstructured":"Zhang Q, Nowak I, Vonderheid EC et al (1996) Activation of Jak\/STAT proteins involved in signal transduction pathway mediated by receptor for interleukin 2 in malignant T lymphocytes derived from cutaneous anaplastic large T-cell lymphoma and Sezary syndrome. Proc Natl Acad Sci USA 93:9148\u20139153","journal-title":"Proc Natl Acad Sci USA"},{"key":"594_CR78","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0002-9440(10)64629-9","volume":"157","author":"Q Zhang","year":"2000","unstructured":"Zhang Q, Raghunath PN, Vonderheid E et al (2000) Lack of phosphotyrosine phosphatase SHP-1 expression in malignant T-cell lymphoma cells results from methylation of the SHP-1 promoter. Am J Pathol 157:1137\u20131146","journal-title":"Am J Pathol"},{"key":"594_CR79","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1046\/j.0022-202x.2001.01436.x","volume":"117","author":"JZ Qin","year":"2001","unstructured":"Qin JZ, Kamarashev J, Zhang CL et al (2001) Constitutive and interleukin-7- and interleukin-15-stimulated DNA binding of STAT and novel factors in cutaneous T cell lymphoma cells. J Invest Dermatol 117:583\u2013589","journal-title":"J Invest Dermatol"},{"key":"594_CR80","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1038\/sj.leu.2403385","volume":"18","author":"VH Sommer","year":"2004","unstructured":"Sommer VH, Clemmensen OJ, Nielsen O et al (2004) In vivo activation of STAT3 in cutaneous T-cell lymphoma. Evidence for an antiapoptotic function of STAT3. Leukemia 18:1288\u20131295","journal-title":"Leukemia"},{"key":"594_CR81","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1038\/sj.leu.2404350","volume":"20","author":"T Krejsgaard","year":"2006","unstructured":"Krejsgaard T, Vetter-Kauczok CS, Woetmann A et al (2006) Jak3- and JNK-dependent vascular endothelial growth factor expression in cutaneous T-cell lymphoma. Leukemia 20:1759\u20131766","journal-title":"Leukemia"},{"key":"594_CR82","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1182\/blood-2014-01-551184","volume":"124","author":"T Krejsgaard","year":"2014","unstructured":"Krejsgaard T, Willerslev-Olsen A, Lindahl LM et al (2014) Staphylococcal enterotoxins stimulate lymphoma-associated immune dysregulation. Blood 124:761\u2013770","journal-title":"Blood"},{"key":"594_CR83","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1182\/blood-2015-08-662353","volume":"127","author":"A Willerslev-Olsen","year":"2016","unstructured":"Willerslev-Olsen A, Krejsgaard T, Lindahl LM et al (2016) Staphylococcal enterotoxin a (SEA) stimulates STAT3 activation and IL-17 expression in cutaneous T-cell lymphoma. Blood 127:1287\u20131296","journal-title":"Blood"},{"key":"594_CR84","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.4161\/15384101.2014.947759","volume":"13","author":"IV Litvinov","year":"2014","unstructured":"Litvinov IV, Cordeiro B, Fredholm S et al (2014) Analysis of STAT4 expression in cutaneous T-cell lymphoma (CTCL) patients and patient-derived cell lines. Cell Cycle 13:2975\u20132982","journal-title":"Cell Cycle"},{"key":"594_CR85","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1182\/blood-2005-07-2813","volume":"107","author":"M Nebozhyn","year":"2006","unstructured":"Nebozhyn M, Loboda A, Kari L et al (2006) Quantitative PCR on 5 genes reliably identifies CTCL patients with 5\u00a0% to 99\u00a0% circulating tumor cells with 90\u00a0% accuracy. Blood 107:3189\u20133196","journal-title":"Blood"},{"key":"594_CR86","doi-asserted-by":"crossref","first-page":"5578","DOI":"10.1158\/0008-5472.CAN-04-1253","volume":"64","author":"R Doom van","year":"2004","unstructured":"van Doom R, Dijkman R, MH V et al (2004) Aberrant expression of the tyrosine kinase receptor EphA4 and the transcription factor twist in Sezary syndrome identified by gene expression analysis. Cancer Res 64:5578\u20135586","journal-title":"Cancer Res"},{"key":"594_CR87","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.4161\/cc.24987","volume":"12","author":"KL Kopp","year":"2013","unstructured":"Kopp KL, Ralfkiaer U, Gjerdrum LM et al (2013) STAT5-mediated expression of oncogenic miR-155 in cutaneous T-cell lymphoma. Cell Cycle 12:1939\u20131947","journal-title":"Cell Cycle"},{"key":"594_CR88","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.4161\/cc.25550","volume":"12","author":"IV Litvinov","year":"2013","unstructured":"Litvinov IV, Pehr K, Sasseville D (2013) Connecting the dots in cutaneous T cell lymphoma (CTCL): STAT5 regulates malignant T cell proliferation via miR-155. Cell Cycle 12:2172\u20132173","journal-title":"Cell Cycle"},{"key":"594_CR89","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jdermsci.2016.05.004","volume":"83","author":"S Furudate","year":"2016","unstructured":"Furudate S, Fujimura T, Kakizaki A et al (2016) Tumor-associated M2 macrophages in mycosis fungoides acquire immunomodulatory function by interferon alpha and interferon gamma. J Dermatol Sci 83:182\u2013189","journal-title":"J Dermatol Sci"},{"key":"594_CR90","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.molimm.2011.12.008","volume":"50","author":"L Bao","year":"2012","unstructured":"Bao L, Shi VY, Chan LS (2012) IL-4 regulates chemokine CCL26 in keratinocytes through the Jak1, 2\/stat 6 signal transduction pathway: implication for atopic dermatitis. Mol Immunol 50:91\u201397","journal-title":"Mol Immunol"},{"key":"594_CR91","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/j.0022-202X.2004.23607.x","volume":"124","author":"H Fujita","year":"2005","unstructured":"Fujita H, Asahina A, Sugaya M et al (2005) Differential production of Th1- and Th2-type chemokines by mouse Langerhans cells and splenic dendritic cells. J Invest Dermatol 124:343\u2013350","journal-title":"J Invest Dermatol"},{"key":"594_CR92","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1177\/154405910808701211","volume":"87","author":"K Ohta","year":"2008","unstructured":"Ohta K, Shigeishi H, Taki M et al (2008) Regulation of CXCL9\/10\/11 in oral keratinocytes and fibroblasts. J Dent Res 87:1160\u20131165","journal-title":"J Dent Res"},{"key":"594_CR93","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.4049\/jimmunol.160.3.1411","volume":"160","author":"V Kodelja","year":"1998","unstructured":"Kodelja V, Muller C, Politz O et al (1998) Alternative macrophage activation-associated CC-chemokine-1, a novel structural homologue of macrophage inflammatory protein-1 alpha with a Th2-associated expression pattern. J Immunol 160:1411\u20131418","journal-title":"J Immunol"},{"key":"594_CR94","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.autrev.2013.10.010","volume":"13","author":"A Antonelli","year":"2014","unstructured":"Antonelli A, Ferrari SM, Giuggioli D et al (2014) Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases. Autoimmun Rev 13:272\u2013280","journal-title":"Autoimmun Rev"},{"key":"594_CR95","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.4049\/jimmunol.1302951","volume":"192","author":"Q Zhang","year":"2014","unstructured":"Zhang Q, Wang HY, Wei F et al (2014) Cutaneous T cell lymphoma expresses immunosuppressive CD80 (B7-1) cell surface protein in a STAT5-dependent manner. J Immunol 192:2913\u20132919","journal-title":"J Immunol"},{"key":"594_CR96","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/nri3405","volume":"13","author":"L Chen","year":"2013","unstructured":"Chen L, Flies DB (2013) Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol 13:227\u2013242","journal-title":"Nat Rev Immunol"},{"key":"594_CR97","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1001\/archdermatol.2010.200","volume":"146","author":"S Samimi","year":"2010","unstructured":"Samimi S, Benoit B, Evans K et al (2010) Increased programmed death-1 expression on CD4+ T cells in cutaneous T-cell lymphoma: implications for immune suppression. Arch Dermatol 146:1382\u20131388","journal-title":"Arch Dermatol"},{"key":"594_CR98","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.4161\/cbt.12.12.18144","volume":"12","author":"RM Abraham","year":"2011","unstructured":"Abraham RM, Zhang Q, Odum N et al (2011) The role of cytokine signaling in the pathogenesis of cutaneous T-cell lymphoma. Cancer Biol Ther 12:1019\u20131022","journal-title":"Cancer Biol Ther"},{"key":"594_CR99","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1182\/blood-2009-04-216671","volume":"114","author":"RA Wilcox","year":"2009","unstructured":"Wilcox RA, Feldman AL, Wada DA et al (2009) B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders. Blood 114:2149\u20132158","journal-title":"Blood"},{"key":"594_CR100","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/DAD.0b013e31821c35cb","volume":"34","author":"K Kantekure","year":"2012","unstructured":"Kantekure K, Yang Y, Raghunath P et al (2012) Expression patterns of the immunosuppressive proteins PD-1\/CD279 and PD-L1\/CD274 at different stages of cutaneous T-cell lymphoma\/mycosis fungoides. Am J Dermatopathol 34:126\u2013128","journal-title":"Am J Dermatopathol"},{"key":"594_CR101","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1038\/leu.2013.118","volume":"27","author":"S Munir","year":"2013","unstructured":"Munir S, Andersen GH, Woetmann A et al (2013) Cutaneous T cell lymphoma cells are targets for immune checkpoint ligand PD-L1-specific, cytotoxic T cells. Leukemia 27:2251\u20132253","journal-title":"Leukemia"},{"key":"594_CR102","first-page":"2682","volume":"7","author":"X Ni","year":"2001","unstructured":"Ni X, Hazarika P, Zhang C et al (2001) Fas ligand expression by neoplastic T lymphocytes mediates elimination of CD8+ cytotoxic T lymphocytes in mycosis fungoides: a potential mechanism of tumor immune escape? Clin Cancer Res 7:2682\u20132692","journal-title":"Clin Cancer Res"},{"key":"594_CR103","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1111\/j.0022-202X.2005.23657.x","volume":"124","author":"X Ni","year":"2005","unstructured":"Ni X, Zhang C, Talpur R et al (2005) Resistance to activation-induced cell death and bystander cytotoxicity via the fas\/fas ligand pathway are implicated in the pathogenesis of cutaneous T cell lymphomas. J Invest Dermatol 124:741\u2013750","journal-title":"J Invest Dermatol"},{"key":"594_CR104","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1046\/j.1365-2133.2000.03656.x","volume":"143","author":"O Zoi-Toli","year":"2000","unstructured":"Zoi-Toli O, Vermeer MH, De VE et al (2000) Expression of Fas and Fas-ligand in primary cutaneous T-cell lymphoma (CTCL): association between lack of Fas expression and aggressive types of CTCL. Br J Dermatol 143:313\u2013319","journal-title":"Br J Dermatol"},{"key":"594_CR105","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1159\/000080999","volume":"67","author":"T Nagasawa","year":"2004","unstructured":"Nagasawa T, Takakuwa T, Takayama H et al (2004) Fas gene mutations in mycosis fungoides: analysis of laser capture-microdissected specimens from cutaneous lesions. Oncology 67:130\u2013134","journal-title":"Oncology"},{"key":"594_CR106","doi-asserted-by":"crossref","first-page":"4780","DOI":"10.1182\/blood-2007-08-109074","volume":"111","author":"E Contassot","year":"2008","unstructured":"Contassot E, Kerl K, Roques S et al (2008) Resistance to FasL and tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in Sezary syndrome T-cells associated with impaired death receptor and FLICE-inhibitory protein expression. Blood 111:4780\u20134787","journal-title":"Blood"},{"key":"594_CR107","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1038\/leu.2015.9","volume":"29","author":"S Esmailzadeh","year":"2015","unstructured":"Esmailzadeh S, Huang Y, MW S et al (2015) BIN1 tumor suppressor regulates Fas\/Fas ligand-mediated apoptosis through c-FLIP in cutaneous T-cell lymphoma. Leukemia 29:1402\u20131413","journal-title":"Leukemia"},{"key":"594_CR108","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.4049\/jimmunol.181.4.2506","volume":"181","author":"M Kasprzycka","year":"2008","unstructured":"Kasprzycka M, Zhang Q, Witkiewicz A et al (2008) Gamma c-signaling cytokines induce a regulatory T cell phenotype in malignant CD4+ T lymphocytes. J Immunol 181:2506\u20132512","journal-title":"J Immunol"},{"key":"594_CR109","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1182\/blood-2010-08-302034","volume":"117","author":"JS Chung","year":"2011","unstructured":"Chung JS, Shiue LH, Duvic M et al (2011) Sezary syndrome cells overexpress syndecan-4 bearing distinct heparan sulfate moieties that suppress T-cell activation by binding DC-HIL and trapping TGF-beta on the cell surface. Blood 117:3382\u20133390","journal-title":"Blood"},{"key":"594_CR110","doi-asserted-by":"crossref","first-page":"6002","DOI":"10.1073\/pnas.91.13.6002","volume":"91","author":"ME Kadin","year":"1994","unstructured":"Kadin ME, Cavaille-Coll MW, Gertz R et al (1994) Loss of receptors for transforming growth factor beta in human T-cell malignancies. Proc Natl Acad Sci USA 91:6002\u20136006","journal-title":"Proc Natl Acad Sci USA"},{"key":"594_CR111","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/bjd.12578","volume":"169","author":"BO Dulmage","year":"2013","unstructured":"Dulmage BO, Geskin LJ (2013) Lessons learned from gene expression profiling of cutaneous T-cell lymphoma. Br J Dermatol 169:1188\u20131197","journal-title":"Br J Dermatol"},{"key":"594_CR112","doi-asserted-by":"crossref","first-page":"4157","DOI":"10.1038\/onc.2010.172","volume":"29","author":"S Nakahata","year":"2010","unstructured":"Nakahata S, Yamazaki S, Nakauchi H et al (2010) Downregulation of ZEB1 and overexpression of Smad 7 contribute to resistance to TGF-beta 1-mediated growth suppression in adult T-cell leukemia\/lymphoma. Oncogene 29:4157\u20134169","journal-title":"Oncogene"},{"key":"594_CR113","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/sj.leu.2403610","volume":"19","author":"C Brender","year":"2005","unstructured":"Brender C, Lovato P, Sommer VH et al (2005) Constitutive SOCS-3 expression protects T-cell lymphoma against growth inhibition by IFNalpha. Leukemia 19:209\u2013213","journal-title":"Leukemia"},{"key":"594_CR114","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1182\/blood.V92.1.252.413k08_252_258","volume":"92","author":"U Dobbeling","year":"1998","unstructured":"Dobbeling U, Dummer R, Laine E et al (1998) Interleukin-15 is an autocrine\/paracrine viability factor for cutaneous T-cell lymphoma cells. Blood 92:252\u2013258","journal-title":"Blood"},{"key":"594_CR115","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1158\/0008-5472.CAN-07-2403","volume":"68","author":"M Marzec","year":"2008","unstructured":"Marzec M, Halasa K, Kasprzycka M et al (2008) Differential effects of interleukin-2 and interleukin-15 versus interleukin-21 on CD4+ cutaneous T-cell lymphoma cells. Cancer Res 68:1083\u20131091","journal-title":"Cancer Res"},{"key":"594_CR116","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/jid.2014.284","volume":"135","author":"C Thode","year":"2015","unstructured":"Thode C, Woetmann A, Wandall HH et al (2015) Malignant T cells secrete galectins and induce epidermal hyperproliferation and disorganized stratification in a skin model of cutaneous T-cell lymphoma. J Invest Dermatol 135:238\u2013246","journal-title":"J Invest Dermatol"},{"key":"594_CR117","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1053\/hupa.2000.20370","volume":"31","author":"KF Izban","year":"2000","unstructured":"Izban KF, Ergin M, Qin JZ et al (2000) Constitutive expression of NF-kappa B is a characteristic feature of mycosis fungoides: implications for apoptosis resistance and pathogenesis. Hum Pathol 31:1482\u20131490","journal-title":"Hum Pathol"},{"key":"594_CR118","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1182\/blood-2005-06-2536","volume":"107","author":"A Sors","year":"2006","unstructured":"Sors A, Jean-Louis F, Pellet C et al (2006) Down-regulating constitutive activation of the NF-kappa B canonical pathway overcomes the resistance of cutaneous T-cell lymphoma to apoptosis. Blood 107:2354\u20132363","journal-title":"Blood"},{"key":"594_CR119","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/leu.2010.66","volume":"24","author":"KL Kopp","year":"2010","unstructured":"Kopp KL, Kauczok CS, Lauenborg B et al (2010) COX-2-dependent PGE(2) acts as a growth factor in mycosis fungoides (MF). Leukemia 24:1179\u20131185","journal-title":"Leukemia"},{"key":"594_CR120","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1038\/leu.2010.221","volume":"24","author":"KL Kopp","year":"2010","unstructured":"Kopp KL, Dabelsteen S, Krejsgaard T et al (2010) COX-2 is a novel target in therapy of mycosis fungoides. Leukemia 24:2127\u20132129","journal-title":"Leukemia"},{"key":"594_CR121","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4049\/jimmunol.1101029","volume":"188","author":"P Kalinski","year":"2012","unstructured":"Kalinski P (2012) Regulation of immune responses by prostaglandin E2. J Immunol 188:21\u201328","journal-title":"J Immunol"},{"key":"594_CR122","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1182\/blood-2012-03-415638","volume":"120","author":"A Rabenhorst","year":"2012","unstructured":"Rabenhorst A, Schlaak M, Heukamp LC et al (2012) Mast cells play a protumorigenic role in primary cutaneous lymphoma. Blood 120:2042\u20132054","journal-title":"Blood"},{"key":"594_CR123","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jaad.2004.03.003","volume":"52","author":"MA Ionescu","year":"2005","unstructured":"Ionescu MA, Rivet J, Daneshpouy M et al (2005) In situ eosinophil activation in 26 primary cutaneous T-cell lymphomas with blood eosinophilia. J Am Acad Dermatol 52:32\u201339","journal-title":"J Am Acad Dermatol"},{"key":"594_CR124","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/j.1365-4632.2010.04228.x","volume":"49","author":"YB Kural","year":"2010","unstructured":"Kural YB, Su O, Onsun N et al (2010) Atopy, IgE and eosinophilic cationic protein concentration, specific IgE positivity, eosinophil count in cutaneous T cell lymphoma. Int J Dermatol 49:390\u2013395","journal-title":"Int J Dermatol"},{"key":"594_CR125","first-page":"5277","volume":"34","author":"S Fredholm","year":"2014","unstructured":"Fredholm S, Gjerdrum LM, Willerslev-Olsen A et al (2014) STAT3 activation and infiltration of eosinophil granulocytes in mycosis fungoides. Anticancer Res 34:5277\u20135286","journal-title":"Anticancer Res"},{"key":"594_CR126","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1038\/jid.2014.206","volume":"134","author":"X Wu","year":"2014","unstructured":"Wu X, Schulte BC, Zhou Y et al (2014) Depletion of M2-like tumor-associated macrophages delays cutaneous T-cell lymphoma development in vivo. J Invest Dermatol 134:2814\u20132822","journal-title":"J Invest Dermatol"},{"key":"594_CR127","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jdermsci.2012.07.007","volume":"68","author":"M Sugaya","year":"2012","unstructured":"Sugaya M, Miyagaki T, Ohmatsu H et al (2012) Association of the numbers of CD163(+) cells in lesional skin and serum levels of soluble CD163 with disease progression of cutaneous T cell lymphoma. J Dermatol Sci 68:45\u201351","journal-title":"J Dermatol Sci"},{"key":"594_CR128","doi-asserted-by":"crossref","unstructured":"Davoine F, Lacy P (2014) Eosinophil cytokines, chemokines, and growth factors: emerging roles in immunity. Front Immunol 5","DOI":"10.3389\/fimmu.2014.00570"},{"key":"594_CR129","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget. 9077","author":"S Ehrentraut","year":"2016","unstructured":"Ehrentraut S, Schneider B, Nagel S et al (2016) Th17 cytokine differentiation and loss of plasticity after SOCS1 inactivation in a cutaneous T-cell lymphoma. Oncotarget. doi: 10.18632\/oncotarget. 9077","journal-title":"Oncotarget"},{"key":"594_CR130","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.1182\/blood.V99.8.2929","volume":"99","author":"CL Berger","year":"2002","unstructured":"Berger CL, Hanlon D, Kanada D et al (2002) The growth of cutaneous T-cell lymphoma is stimulated by immature dendritic cells. Blood 99:2929\u20132939","journal-title":"Blood"},{"key":"594_CR131","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/cas.12314","volume":"105","author":"Y Komohara","year":"2014","unstructured":"Komohara Y, Jinushi M, Takeya M (2014) Clinical significance of macrophage heterogeneity in human malignant tumors. Cancer Sci 105:1\u20138","journal-title":"Cancer Sci"},{"key":"594_CR132","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0959-8049(97)00186-X","volume":"33","author":"A Vacca","year":"1997","unstructured":"Vacca A, Moretti S, Ribatti D et al (1997) Progression of mycosis fungoides is associated with changes in angiogenesis and expression of the matrix metalloproteinases 2 and 9. Eur J Cancer 33:1685\u20131692","journal-title":"Eur J Cancer"},{"key":"594_CR133","doi-asserted-by":"crossref","first-page":"15235","DOI":"10.18632\/oncotarget.3837","volume":"6","author":"B Lauenborg","year":"2015","unstructured":"Lauenborg B, Christensen L, Ralfkiaer U et al (2015) Malignant T cells express lymphotoxin alpha and drive endothelial activation in cutaneous T cell lymphoma. Oncotarget 6:15235\u201315249","journal-title":"Oncotarget"},{"key":"594_CR134","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/his.12445","volume":"66","author":"A Pileri","year":"2015","unstructured":"Pileri A, Agostinelli C, Righi S et al (2015) Vascular endothelial growth factor a (VEGFA) expression in mycosis fungoides. Histopathology 66:173\u2013181","journal-title":"Histopathology"},{"key":"594_CR135","doi-asserted-by":"crossref","first-page":"819","DOI":"10.3109\/10428194.2012.726720","volume":"54","author":"IH Pedersen","year":"2013","unstructured":"Pedersen IH, Willerslev-Olsen A, Vetter-Kauczok C et al (2013) Vascular endothelial growth factor receptor-3 expression in mycosis fungoides. Leuk Lymphoma 54:819\u2013826","journal-title":"Leuk Lymphoma"},{"key":"594_CR136","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1182\/blood.V94.3.902.415k23_902_908","volume":"94","author":"AH Rook","year":"1999","unstructured":"Rook AH, Wood GS, Yoo EK et al (1999) Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses. Blood 94:902\u2013908","journal-title":"Blood"},{"key":"594_CR137","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1001\/archderm.138.9.1137","volume":"138","author":"KR Suchin","year":"2002","unstructured":"Suchin KR, Junkins-Hopkins JM, Rook AH (2002) Treatment of stage IA cutaneous T-cell lymphoma with topical application of the immune response modifier imiquimod. Arch Dermatol 138:1137\u20131139","journal-title":"Arch Dermatol"},{"key":"594_CR138","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1182\/blood-2004-01-0360","volume":"104","author":"R Dummer","year":"2004","unstructured":"Dummer R, Hassel JC, Fellenberg F et al (2004) Adenovirus-mediated intralesional interferon-gamma gene transfer induces tumor regressions in cutaneous lymphomas. Blood 104:1631\u20131638","journal-title":"Blood"},{"key":"594_CR139","doi-asserted-by":"crossref","first-page":"4142","DOI":"10.1182\/blood-2004-03-1190","volume":"104","author":"M Wysocka","year":"2004","unstructured":"Wysocka M, Benoit BM, Newton S et al (2004) Enhancement of the host immune responses in cutaneous T-cell lymphoma by CpG oligodeoxynucleotides and IL-15. Blood 104:4142\u20134149","journal-title":"Blood"},{"key":"594_CR140","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.jaad.2006.06.038","volume":"55","author":"M Duvic","year":"2006","unstructured":"Duvic M, Sherman ML, Wood GS et al (2006) A phase II open-label study of recombinant human interleukin-12 in patients with stage IA, IB, or IIA mycosis fungoides. J Am Acad Dermatol 55:807\u2013813","journal-title":"J Am Acad Dermatol"},{"key":"594_CR141","doi-asserted-by":"crossref","first-page":"524","DOI":"10.3816\/CLM.2007.n.037","volume":"7","author":"M Wysocka","year":"2007","unstructured":"Wysocka M, Newton S, Benoit BM et al (2007) Synthetic imidazoquinolines potently and broadly activate the cellular immune response of patients with cutaneous T-cell lymphoma: synergy with interferon-gamma enhances production of interleukin-12. Clin Lymphoma Myeloma 7:524\u2013534","journal-title":"Clin Lymphoma Myeloma"},{"key":"594_CR142","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.jaad.2009.12.052","volume":"63","author":"YH Kim","year":"2010","unstructured":"Kim YH, Girardi M, Duvic M et al (2010) Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma. J Am Acad Dermatol 63:975\u2013983","journal-title":"J Am Acad Dermatol"},{"key":"594_CR143","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1186\/1479-5876-11-226","volume":"11","author":"N Accart","year":"2013","unstructured":"Accart N, Urosevic-Maiwald M, Dummer R et al (2013) Lymphocytic infiltration in the cutaneous lymphoma microenvironment after injection of TG 1042. J Transl Med 11:226","journal-title":"J Transl Med"},{"key":"594_CR144","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1182\/blood-2015-02-630335","volume":"126","author":"AH Rook","year":"2015","unstructured":"Rook AH, Gelfand JM, Wysocka M et al (2015) Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphoma. Blood 126:1452\u20131461","journal-title":"Blood"},{"key":"594_CR145","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1182\/blood.V89.1.32","volume":"89","author":"CM Jackow","year":"1997","unstructured":"Jackow CM, Cather JC, Hearne V et al (1997) Association of erythrodermic cutaneous T-cell lymphoma, superantigen-positive Staphylococcus aureus, and oligoclonal T-cell receptor V beta gene expansion. Blood 89:32\u201340","journal-title":"Blood"},{"key":"594_CR146","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/j.1365-2133.2008.08612.x","volume":"159","author":"R Talpur","year":"2008","unstructured":"Talpur R, Bassett R, Duvic M (2008) Prevalence and treatment of Staphylococcus aureus colonization in patients with mycosis fungoides and Sezary syndrome. Br J Dermatol 159:105\u2013112","journal-title":"Br J Dermatol"},{"key":"594_CR147","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.jaad.2008.08.030","volume":"59","author":"V Nguyen","year":"2008","unstructured":"Nguyen V, Huggins RH, Lertsburapa T et al (2008) Cutaneous T-cell lymphoma and Staphylococcus aureus colonization. J Am Acad Dermatol 59:949\u2013952","journal-title":"J Am Acad Dermatol"},{"key":"594_CR148","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1182\/blood-2006-04-017863","volume":"109","author":"A Woetmann","year":"2007","unstructured":"Woetmann A, Lovato P, Eriksen KW et al (2007) Nonmalignant T cells stimulate growth of T-cell lymphoma cells in the presence of bacterial toxins. Blood 109:3325\u20133332","journal-title":"Blood"},{"key":"594_CR149","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1365-2133.1995.tb02485.x","volume":"133","author":"Y Tokura","year":"1995","unstructured":"Tokura Y, Yagi H, Ohshima A et al (1995) Cutaneous colonization with staphylococci influences the disease activity of Sezary syndrome: a potential role for bacterial superantigens. Br J Dermatol 133:6\u201312","journal-title":"Br J Dermatol"},{"key":"594_CR150","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0190-9622(96)90683-0","volume":"35","author":"M Duvic","year":"1996","unstructured":"Duvic M, Hester JP, Lemak NA (1996) Photopheresis therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol 35:573\u2013579","journal-title":"J Am Acad Dermatol"},{"key":"594_CR151","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1016\/j.jid.2016.03.042","volume":"136","author":"R Doom van","year":"2016","unstructured":"van Doom R, Slieker RC, Boonk SE et al (2016) Epigenomic analysis of Sezary syndrome defines patterns of aberrant DNA methylation and identifies diagnostic markers. J Invest Dermatol 136:1876\u20131884","journal-title":"J Invest Dermatol"},{"key":"594_CR152","doi-asserted-by":"crossref","first-page":"3886","DOI":"10.1200\/JCO.2005.11.353","volume":"23","author":"R Doom van","year":"2005","unstructured":"van Doom R, Zoutman WH, Dijkman R et al (2005) Epigenetic profiling of cutaneous T-cell lymphoma: promoter hypermethylation of multiple tumor suppressor genes including BCL7a, PTPRG, and p 73. J Clin Oncol 23:3886\u20133896","journal-title":"J Clin Oncol"},{"key":"594_CR153","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/nrc2734","volume":"9","author":"H Yu","year":"2009","unstructured":"Yu H, Pardoll D, Jove R (2009) STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 9:798\u2013809","journal-title":"Nat Rev Cancer"},{"key":"594_CR154","doi-asserted-by":"crossref","first-page":"4725","DOI":"10.1073\/pnas.1424795112","volume":"112","author":"MT Cheah","year":"2015","unstructured":"Cheah MT, Chen JY, Sahoo D et al (2015) CD14-expressing cancer cells establish the inflammatory and proliferative tumor microenvironment in bladder cancer. Proc Natl Acad Sci USA 112:4725\u20134730","journal-title":"Proc Natl Acad Sci USA"},{"key":"594_CR155","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1158\/0008-5472.CAN-15-0125","volume":"75","author":"X Ma","year":"2015","unstructured":"Ma X, Aoki T, Tsuruyama T et al (2015) Definition of prostaglandin E2-EP2 signals in the colon tumor microenvironment that amplify inflammation and tumor growth. Cancer Res 75:2822\u20132832","journal-title":"Cancer Res"},{"key":"594_CR156","doi-asserted-by":"crossref","first-page":"3630","DOI":"10.1158\/1078-0432.CCR-15-1434","volume":"22","author":"Y Lou","year":"2016","unstructured":"Lou Y, Diao L, Cuentas ER et al (2016) Epithelial-mesenchymal transition is associated with a distinct tumor microenvironment including elevation of inflammatory signals and multiple immune checkpoints in lung adenocarcinoma. Clin Cancer Res 22:3630\u20133642","journal-title":"Clin Cancer Res"},{"key":"594_CR157","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1136\/jcp.2004.025072","volume":"58","author":"AG Bais","year":"2005","unstructured":"Bais AG, Beckmann I, Lindemans J et al (2005) A shift to a peripheral Th2-type cytokine pattern during the carcinogenesis of cervical cancer becomes manifest in CIN III lesions. J Clin Pathol 58:1096\u20131100","journal-title":"J Clin Pathol"},{"key":"594_CR158","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1158\/0008-5472.CAN-10-2907","volume":"71","author":"M Tosolini","year":"2011","unstructured":"Tosolini M, Kirilovsky A, Mlecnik B et al (2011) Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. Cancer Res 71:1263\u20131271","journal-title":"Cancer Res"},{"key":"594_CR159","doi-asserted-by":"crossref","first-page":"2802","DOI":"10.1073\/pnas.1108781108","volume":"109","author":"VN Kristensen","year":"2012","unstructured":"Kristensen VN, Vaske CJ, Ursini-Siegel J et al (2012) Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signaling. Proc Natl Acad Sci USA 109:2802\u20132807","journal-title":"Proc Natl Acad Sci USA"},{"key":"594_CR160","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.humimm.2014.01.011","volume":"75","author":"P Gaur","year":"2014","unstructured":"Gaur P, Singh AK, Shukla NK et al (2014) Inter-relation of Th1, Th2, Th17 and Treg cytokines in oral cancer patients and their clinical significance. Hum Immunol 75:330\u2013337","journal-title":"Hum Immunol"},{"key":"594_CR161","doi-asserted-by":"crossref","unstructured":"Datta J, Berk E, Xu S et al (2015) Anti-HER2 CD4(+) T-helper type 1 response is a novel immune correlate to pathologic response following neoadjuvant therapy in HER2-positive breast cancer. Breast Cancer Res 17","DOI":"10.1186\/s13058-015-0584-1"},{"key":"594_CR162","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/nature15520","volume":"527","author":"D Peng","year":"2015","unstructured":"Peng D, Kryczek I, Nagarsheth N et al (2015) Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy. Nature 527:249\u2013253","journal-title":"Nature"},{"key":"594_CR163","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.ccell.2015.04.011","volume":"27","author":"W Si","year":"2015","unstructured":"Si W, Huang W, Zheng Y et al (2015) Dysfunction of the reciprocal feedback loop between GATA3- and ZEB2-nucleated repression programs contributes to breast cancer metastasis. Cancer Cell 27:822\u2013836","journal-title":"Cancer Cell"},{"key":"594_CR164","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1158\/0008-5472.CAN-15-1801-T","volume":"76","author":"ML De","year":"2016","unstructured":"De ML, Wormann S, Brunetto E et al (2016) Basophil recruitment into tumor-draining lymph nodes correlates with Th2 inflammation and reduced survival in pancreatic cancer patients. Cancer Res 76:1792\u20131803","journal-title":"Cancer Res"},{"key":"594_CR165","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1158\/0008-5472.CAN-15-1938","volume":"76","author":"N Nagarsheth","year":"2016","unstructured":"Nagarsheth N, Peng D, Kryczek I et al (2016) PRC2 epigenetically silences Th1-type chemokines to suppress effector T-cell trafficking in colon cancer. Cancer Res 76:275\u2013282","journal-title":"Cancer Res"},{"key":"594_CR166","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1158\/2159-8290.CD-11-0241","volume":"2","author":"K Subbaramaiah","year":"2012","unstructured":"Subbaramaiah K, Morris PG, Zhou XK et al (2012) Increased levels of COX-2 and prostaglandin E2 contribute to elevated aromatase expression in inflamed breast tissue of obese women. Cancer Discov 2:356\u2013365","journal-title":"Cancer Discov"}],"container-title":["Seminars in Immunopathology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00281-016-0594-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00281-016-0594-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00281-016-0594-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,20]],"date-time":"2023-08-20T10:51:43Z","timestamp":1692528703000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00281-016-0594-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,7]]},"references-count":166,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["594"],"URL":"https:\/\/doi.org\/10.1007\/s00281-016-0594-9","relation":{},"ISSN":["1863-2297","1863-2300"],"issn-type":[{"value":"1863-2297","type":"print"},{"value":"1863-2300","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,7]]}}}